Brain tumor patients get Virus-Radiation combo in early trial

NCT ID NCT05686798

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new approach for people with recurrent high-grade astrocytomas, a type of aggressive brain cancer. During surgery to remove the tumor, doctors inject a modified virus directly into the brain cavity, followed by targeted radiation. The main goal is to find the safest dose of the virus and see if it boosts the immune system's attack on the cancer. Only 18 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ad5-yCD/mutTKSR39rep-ADP adenovirus (a modified virus injected into the brain tumor during surgery)
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent aggressive brain tumors that have come back after standard therapy.
What could go wrong
This is a very early phase 1 trial with only 18 people, focused on safety and dosing. The virus is injected directly into the brain, which carries risks like infection, swelling, or inflammation. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Henry Ford Health System

    RECRUITING

    Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.